BMRA Stock — Biomerica Inc

Biomerica Inc (BMRA)

Updated October 16, 2026.

BMRA is a Stock. Total return is -96.0% over the past 41.9 years.

Biomerica is a biomedical technology company that develops, manufactures, and markets diagnostic test kits for detecting diseases, food intolerances, and medical conditions through analysis of blood, urine, nasal, or fecal samples, along with contract manufacturing services and diagnostic-guided therapy products for gastrointestinal diseases. The company does not currently have an established distribution schedule. Biomerica appeals to investors seeking exposure to diagnostic healthcare innovation rather than current income.

BMRA performance

Price and return data through 2026-10-16.

Total return is -96.0% over the past 41.9 years. Over the past year its total return — price change plus distributions reinvested — is -38.5%. Its deepest 1-year drawdown was 53.4%.

BMRA key facts

Asset type

Stock

Asset class

Equity

Inception date

11/05/1984

Distribution frequency

None

Last close

$1.85 (as of 2026-10-16)

Market cap

$8,508,091

Average volume

13191.0

Beta

0.381

Payout ratio

0.0%

Forward P/E

4.8077

EPS

$-1.30

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BMRA risks and drawbacks

The deepest 1-year drawdown on record here is 53.4%.

Who may consider BMRA — and who may not

It is a weaker fit for investors who need monthly cash flow (BMRA does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BMRA

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions